Immunocore slides on earnings miss despite revenue growth
Biotech company posts wider-than-expected loss, forecasts moderating growth for KIMMTRAK in 2026
Immunocore Holdings shares extended losses Wednesday after the British biotechnology company reported a wider-than-expected quarterly loss and signaled slowing revenue growth for its flagship cancer treatment, overshadowing a year of strong sales expansion.
The company reported a fourth-quarter net loss of $30.1 million, or 60 cents per share, missing analyst estimates of a 24-cent loss by more than 150%, according to the company's earnings release. The disappointing bottom-line performance came despite revenue of $104.5 million for the quarter, which topped the $101.8 million consensus forecast.
Full-year revenue reached $400 million, representing 29% growth compared with 2024, driven primarily by KIMMTRAK, the company's pioneering immunotherapy for uveal melanoma. However, Immunocore forecast "moderating revenue growth" for KIMMTRAK in 2026, a guidance that disappointed investors accustomed to the drug's rapid expansion since its approval.
The company's net loss for the full year narrowed to $35.5 million from $51.1 million in 2024, indicating progress toward profitability. Immunocore ended 2025 with a robust cash position of $864.2 million, providing substantial runway for its clinical development programs despite the earnings shortfall.
Research and development expenses weighed heavily on the quarter, reaching $78.8 million in the fourth quarter and $274.9 million for the full year. Selling, general and administrative costs totaled $42.6 million in Q4 and $165.4 million for 2025, reflecting the company's investment in commercial infrastructure for KIMMTRAK and preparation for future product launches.
Chief Executive Bahija Jallal emphasized clinical execution as the company's top priority for 2026, with anticipated key data in oncology and the first trial initiation in autoimmune disease. Immunocore plans to enter the clinic with its first autoimmune candidate in the first half of 2026, representing a significant expansion beyond its oncology focus.
Investors are particularly focused on the TEBE-AM registrational Phase 3 trial, which remains on track to complete enrollment in the first half of 2026. The company expects to report topline overall survival data from this pivotal study as early as the second half of 2026, which could serve as a major catalyst for the stock.
Analysts maintain a generally positive outlook on Immunocore, with a consensus target price of $66.57, according to market data, well above current trading levels. The stock carries 13 buy ratings and three hold ratings from covering analysts, with no sell recommendations, suggesting that many on Wall Street view the earnings miss as temporary rather than reflective of fundamental business deterioration.
The company's heavy institutional ownership, exceeding 105%, indicates strong conviction among large investors despite the recent volatility. Immunocore's market capitalization stands at approximately $1.64 billion, with shares trading around $33.68.
The mixed results highlight the challenges facing commercial-stage biotechnology companies as they balance revenue growth against the substantial investments required to build clinical pipelines and commercial organizations. While KIMMTRAK's sales trajectory has been impressive, reaching $400 million in its first full commercial year, the guidance for moderating growth suggests market saturation or competitive pressures may be emerging.
Investors will be watching closely for updates on the TEBE-AM trial and the company's autoimmune program launch, both of which could determine whether Immunocore can sustain its growth momentum beyond its lead product. The strong cash position provides flexibility, but the path to profitability remains uncertain as R&D investments continue to mount ahead of potential regulatory milestones.